Navigation Links
ADVENTRX Announces Consolidation of Clinical and Management Positions
Date:1/30/2008

SAN DIEGO, Jan. 30 /PRNewswire-FirstCall/ -- ADVENTRX Pharmaceuticals, Inc. (Amex: ANX), a biopharmaceutical research and development company focused on commercializing proprietary product candidates for the treatment of cancer and infectious diseases, announced today that Evan M. Levine, the company's current Chief Executive Officer, has resumed his position as Chief Executive Officer and President, a position he held from September 2004 through September 2006.

The company also announced that James A. Merritt's employment relationship with the company ended, effective January 29, 2008. Dr. Merritt previously served as the company's President and Chief Medical Officer. In connection with these events, the underlying responsibilities of the Chief Medical Officer and President positions have been consolidated. Joachim P.H. Schupp, M.D., who has served as the company's Vice President, Medical Affairs since August 2006, will lead the company's clinical group and assume Dr. Merritt's clinical responsibilities, and Mr. Levine will resume the corporate responsibilities of the President.

"We have an experienced team that will continue to rapidly advance our lead programs and we are excited by our continued progress and anticipate achieving additional milestones in 2008," stated Mr. Levine. "On behalf of our board of directors and the entire management team, we thank Jay for his contributions to the company and wish him well," added Mr. Levine.

About ADVENTRX Pharmaceuticals

ADVENTRX Pharmaceuticals seeks to improve the performance and safety of existing treatments by addressing significant problems such as drug metabolism, bioavailability, excessive toxicity and treatment resistance. More information can be found on the
'/>"/>

SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
2. ADVENTRX Pharmaceuticals to Present at the 2007 Thomas Weisel Partners Healthcare Conference
3. ADVENTRX Pharmaceuticals to Present at the 20th Annual Bear Stearns Healthcare Conference
4. ADVENTRX Announces ANX-514 Clinical Development Plan Affirmed by the FDA
5. ADVENTRX Pharmaceuticals to Present at the ThinkEquity Partners Fifth Annual Growth Conference
6. ADVENTRX Pharmaceuticals to Present at the 2007 UBS Global Life Sciences Conference
7. ADVENTRX to Present ANX-514 Preclinical Data at 2007 AACR-NCI-EORTC International Conference
8. ADVENTRX Pharmaceuticals to Present at the 2007 BIOInvestor Forum
9. ADVENTRX Appoints Vice President of Commercialization
10. ADVENTRX Pharmaceuticals Reports Third Quarter 2007 Financial Results
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... “Preparative & Process Chromatography Market by Instrument ... Buffers, Valves, Guages, Seals), Accessories, Services, End User ... 2019” provides a detailed overview of the major ... strategies impacting the preparative and process chromatography market ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
(Date:12/24/2014)... On Friday, December 19, 2014, President Obama signed ... Appropriations Act of 2015, which for the first time, ... the Congressionally Directed Medical Research Programs (CDMRP) administered by ... working in conjunction with its allies on Capitol Hill, ...
(Date:12/24/2014)... (PRWEB) December 23, 2014 The ... as its definition, classification, application and industry overview. ... and product cost structure. Production is separated by ... upstream raw materials, equipment, downstream client survey, marketing ...
Breaking Biology Technology:Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 2Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 3Preparative and Process Chromatography Market is expected to reach $9 billion by 2019 - New Report by Marketsandmarkets 4Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2
... in the question, if the entry of veterinary medicinal ... environmental relevance. In a recent study, published in the ... now focused on the so far less investigated benzimidazole ... data set on fate and behavior of veterinary medicinal ...
... American Society of,Hematology (ASH) will host its annual ... Center on Friday, December 7, 2007, beginning at,8:00 ... in hematology,the biological sciences, and medical research, is ... This year, students will have the,opportunity to explore ...
... Cost, Savings and Avoidance of Approximately $1.5 Billion by 2010 and Incur, Associated ... ... 11% Increase in Indicative Dividend for 2008 and Declares ... Quarterly Dividend, * Revises 2007 Full-Year GAAP EPS Guidance to ...
Cached Biology Technology:New insights into the fate of anti-parasitics in manure and manured soils 2ASH Holds a Special Symposium to Interest High School Students in Biomedical Research 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 2Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 3Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 4Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 5Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 6Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 7Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 8Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 9Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 10Bristol-Myers Squibb Company Outlines Strategy and Productivity Transformation Initiative During Update to Investment Community 11
(Date:12/17/2014)...  HITLAB SM announced today its completion of a ... to current U.S. Food and Drug Administration (FDA) regulations. ... and smart phone application trials utilizing the highest principles ... is determined to improve global healthcare access, quality, and ...
(Date:12/17/2014)... Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has announced the ... report to their offering. ... in this market is the increasing demand for medical ... of patient data for quick and correct diagnosis during ...
(Date:12/15/2014)... , Dec. 12, 2014 Research and Markets ... "Global Facial Recognition Market 2015-2019" report to ... Facial recognition is a technology used for ... overall facial feature of a person such as nose, ...
Breaking Biology News(10 mins):HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 2Global Facial Recognition Market 2015-2019: Key Vendors are 3M Cogent, Cognitec Systems, NEC and Safran Group 3
... in grain crops should be expanded to include so-called ... forms in the body, a new study concludes. It ... . Chiara Dall,Asta and colleagues explain that molds ... toxic substances termed mycotoxins. Some health experts regard mycotoxins ...
... promises to allow expanded use of a mainstay biological ... pest-resistance concerns of traditional insecticides, scientists are reporting. The ... technique (SIT) appears in the journal ACS Synthetic ... the Lepidoptera, a large family of insects with a ...
... of Manchester is leading the way when it comes to ... training package to teach students and scientists how to best ... hoped it will encourage more researchers working on a range ... humble fly. The unique scheme has been put together ...
Cached Biology News:World first for fly research 2World first for fly research 3
...
...
... filters allow for the rapid isolation of DNA ... gel slice in the spin filter, centrifuge for ... is recovered. There is no need to melt ... filters can also be used for buffer exchange, ...
ChemiArray Human Cytokine Antibody Array VII, 60 cytokines per membrane...
Biology Products: